<DOC>
	<DOCNO>NCT02225093</DOCNO>
	<brief_summary>This study evaluate daily enzalutamide affect metabolism caffeine dextromethorphan men prostate cancer measure concentration drug metabolite plasma .</brief_summary>
	<brief_title>A Study Evaluate How Daily Dosing With Enzalutamide Affects Metabolism Caffeine Dextromethorphan Men With Prostate Cancer</brief_title>
	<detailed_description>This open-label , fixed-sequence , crossover drug-drug interaction study subject prostate cancer . Screening take place Day -28 Day -7 , subject admitted clinic Day -1 remain Day 4 . On Day 1 , receive single oral cocktail contain caffeine dextromethorphan plus dose enzalutamide placebo order ass possible effect excipients enzalutamide formulation . On Days 1 3 blood sample pharmacokinetic ( PK ) assessment collect . From Days 4 54 , ( Day 55 subject roll extension study ) subject take daily oral dose enzalutamide . On Day 28 , subject return clinic plasma sample take determine enzalutamide PK exposure . From Days 52 55 re-admitted clinic plasma sample collect Day 52 enzalutamide PK exposure.On Day 53 , subject receive single oral cocktail caffeine dextromethorphan concomitantly enzalutamide . PK sample collect Days 53 55 . From Day 55 onwards , subject experience clinical benefit may roll extension study . Only subject enroll extension study continue receive enzalutamide otherwise daily dose enzalutamide discontinue Day 54 . An End Study Visit ( ESV ) take place approximately 30 day ( Â±7 day ) last dose enzalutamide .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Subject male age 18 year old old ( screen ) histologically confirm prostate cancer ( stage ) androgen deprivation therapy indicate ( except indicate neoadjuvant/adjuvant setting ) . Subjects may ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue undergone prior bilateral orchiectomy screening . Subject progressive disease prostatespecific antigen ( PSA ) imaging . Subject receive 2 prior chemotherapy regimen . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Male subject must use condom sex pregnant woman . Male subject female spouse/partners childbearing potential must use 2 acceptable method birth control start screen continue throughout study period 3 month final study drug administration . Subject estimate life expectancy least 6 month . Subject confirm CYP2D6 poor metabolizer , CYP2D6 ultrarapid metabolizer status base genotyping analysis . Subject know metastasis liver hepatic disorder could affect drug metabolism deem clinically significant investigator discussion sponsor . Subject undergone major surgery within 4 week prior day 1 . Subject receive treatment chemotherapy within 4 week prior enrollment ( day 1 visit ) plan initiate treatment chemotherapy study . Subject use concomitant medication potent inducer and/or inhibitor CYP1A2 , CYP2C8 , CYP2D6 , CYP3A4 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Caffeine</keyword>
	<keyword>Dextromethorphan</keyword>
	<keyword>CYP1A2</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Phase 1</keyword>
</DOC>